CUDC-101 is a potent multitargeted HDAC, EGFR and HER2 inhibitor with IC50 of 4.4, 2.4, and 15.7 nM, respectively. CUDC-101 synergistically blocked key regulators of EGFR/HER2 signaling pathways, also attenuating multiple compensatory pathways, such as AKT, HER3, and MET, which enable cancer cells to escape the effects of conventional EGFR/HER2 inhibitors.
|Cell lines||A431, H292 and BT474 cells|
|Preparation method||Cell growth, viability, and apoptosis assay Cancer cell lines were obtained from the American Type Culture Collection and were maintained according to the supplier's instructions. Cancer cell lines were plated at 5,000 to 10,000 cells per well in 96-well flat-bottomed plates with varying concentrations of compounds. The cells were incubated with compounds for 72 hours in the presence of 0.5% of fetal bovine serum. Growth inhibition was assessed by an ATP content assay using the Perkin-Elmer ATPlite kit. Apoptosis was routinely assessed by measuring the activities of caspase-3 and caspase-7 using the Promega Apo-ONE Homogeneous Assay kit.|
|Concentrations||0, 0.1, 1, or 10 µM|
|Animal models||HepG2 hepatoma cells xenograft models nude mice|
|Formulation||30% Captisol solution|
|Dosages||120 mg/kg daily|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Source||Oncotarget (2015). Figure 5. CUDC-101|
|Cell Lines||ATC cells|
|Incubation Time||24 h|
|Results||Treatment with CUDC-101 also significantly reduced the expression of survivin and XIAP, known inhibitors of caspases|
CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.
Lai et al. Cancer Res. 2010 May 1;70(9):3647-56. PMID: 20388807.
Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
Cai et al. J Med Chem. 2010 Mar 11;53(5):2000-9. PMID: 20143778.
|Related HDAC Products|
Chidamide is a low nanomolar inhibitor of HDAC1, 2, 3, and 10, the HDAC isotypes well documented to be associated with the malignant phenotype with IC50 values of 95, 160, 67, 78 nM for HDAC1, 2, 3, 10 respectively.
TMP195 is a selective, first-in-class, class IIa HDAC inhibitor with IC50 of 300 nM in cell-based class IIa HDAC assays.
WT-161 is a potent and selective HDAC6 inhibitor with an IC50 of 0.40 nM.
EDO-S101 is a pan HDAC inhibitor; inhibits HDAC1, HDAC2 and HDAC3 with IC50 values of 9, 9 and 25 nM, respectively.
Citarinostat (ACY-241) is an orally available selective HDAC6 inhibitor with IC50 of 2.6 nM and 46 nM for HDAC6 and HDAC3, respectively. It has 13 to 18-fold selectivity towards HDAC6 in comparison to HDAC1-3.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.